Levosimendan for exercise limitation in PH-HFpEF
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests if the drug levosimendan can help people with a specific type of pulmonary hypertension (PH-HFpEF) feel less tired and breathless during daily activities, and improve their exercise ability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have heart failure symptoms like shortness of breath or fatigue, even with mild activity (NYHA Class II–IV).
- You have been diagnosed with a specific type of pulmonary hypertension called WHO Group 2 PH-HFpEF, confirmed by a heart catheterization.
- You have had a qualifying echocardiogram and a 6-minute walk test.
- You agree not to become pregnant or father a child during the study, and you can use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This long-term study gives continued access to the oral levosimendan medication for people who finished the earlier TNX-103 study. The goal is to see if ongoing treatment remains safe and helpful.
This trial tests a medication called levosimendan to help people with severe heart failure who are still very short of breath even after standard treatment. The goal is to see if it can improve symptoms and help you feel better.
This trial tests an investigational drug called VS-041 to see if it's safe and helps people with a type of heart failure where the heart pumps well but doesn't relax properly (HFpEF). It may be an option if you are 50 or older and have stable heart failure symptoms.
This trial tests an investigational drug called HS235 in people who have both obesity (BMI 30-50) and a specific type of heart failure with preserved pumping function, along with high blood pressure in the lungs. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This study tests whether giving levosimendan early (a heart-strengthening medicine) improves outcomes compared with placebo, on top of standard inotropic support, in people with cardiogenic shock. It mainly looks at whether patients have fewer serious complications or deaths.
Hear when a new Pulmonary Hypertension Associated With HFpEF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.